Samsung Bioepis Presents Results of SB5 (biosimilar, adalimumab) in P-I and (PROPER) Study for Rheumatoid Arthritis and Other Inflammatory Diseases at EULAR 202
- The P-I study evaluates the new SB5 formulation (40mg/0.4 mL) vs the original SB5 formulation (40mg/0.8 mL) in male patients with RA & other inflammatory diseases. The results showed the clinical equivalence b/w 2 formulations, were well tolerated with similar safety profiles
- The pan-EU real-world (PROPER) study evaluates Humira vs SB5 in 1000 patients with RA, axSpA, PsA, UC, or CD. Eligible patients had been transitioned to SB5 as part of routine treatment following 16wks. with reference ADL.
- Results were recorded for 24wks. prior to the switch & 48wks. following the switch to SB5. The study showed that adalimumab therapy's effectiveness persisted on the biosimilar after 48wks. and the majority of patients opted to continue on SB
Ref: Samsung Bioepis | Image: Samsung Bioepis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].